BeOne Medicines officer sells 1,533 depositary shares

Q: How many ONC ADS did Titus B. Ball acquire?

On November 6, 2026, Ball acquired 880 ADS at $207.55 per share and 679 ADS at $159.03 per share. Each ADS represents 13 ordinary shares.

The option awards’ vesting schedules include 25% initial vesting and 36 successive monthly installments, subject to continued service.

Available on EDGAR 11/10/2026 - 05:00 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:59 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BeOne Medicines Ltd. Principal Accounting Officer Titus B. Ball reported exercise or conversion transactions involving options representing 11,440 and 8,827 ordinary shares, with exercise prices of $15.97 and $12.23, respectively, on November 6, 2026. He also acquired 880 American Depositary Shares (ADS) at $207.55 and 679 ADS at $159.03.

Ball sold 1,533 ADS at a weighted-average price of $405.5528; the reported sale prices ranged from $405.25 to $406.15. He also sold 26 ADS at $406.34. Each ADS represents 13 ordinary shares. His reported direct holdings were 97,929 ordinary shares as of November 6, 2026.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Ball Titus B.

Role Principal Accounting Officer

Sold 1,559 shs ($632K)

Approx. gross sale proceeds $632K

Approx. exercise cost $291K

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy) ^{F3, F4}	11,440	$0.00	$0.00
Exercise	Share Option (Right to Buy) ^{F3, F5}	8,827	$0.00	$0.00
Exercise	American Depositary Shares ^F1	880	$207.55	$183K
Exercise	American Depositary Shares ^F1	679	$159.03	$108K
Sale	American Depositary Shares ^{F1, F2}	1,533	$405.5528	$622K
Sale	American Depositary Shares ^F1	26	$406.34	$11K
Holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 9,750 options (Direct); American Depositary Shares — 0 shares (Direct); Ordinary Shares — 97,929 shares (Direct)

Footnotes (5)

F1. Each American Depositary Share represents 13 Ordinary Shares.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $405.25 to $406.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
F4. These securities vest over a four-year period as follows: 25% on August 31, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service.
F5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Key Figures

Option underlying shares: 11,440 ordinary shares Option underlying shares: 8,827 ordinary shares ADS acquired: 880 ADS at $207.55 per ADS +4 more

7 metrics

Option underlying shares 11,440 ordinary shares Exercise price $15.97 per ordinary share; November 6, 2026

Option underlying shares 8,827 ordinary shares Exercise price $12.23 per ordinary share; November 6, 2026

ADS acquired 880 ADS at $207.55 per ADS November 6, 2026

ADS acquired 679 ADS at $159.03 per ADS November 6, 2026

ADS sold 1,533 ADS at a weighted-average price of $405.5528 per ADS Reported sale prices ranged from $405.25 to $406.15; November 6, 2026

ADS sold 26 ADS at $406.34 per ADS November 6, 2026

Direct ordinary shares following transactions 97,929 ordinary shares As of November 6, 2026

Key Terms

American Depositary Share, weighted average price, exercise price, vesting

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

exercise price financial

"the exercise price therefore are represented in ordinary shares"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"the remaining shares vesting in 36 equal successive monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ONC ADS did Titus B. Ball sell and at what prices?

On November 6, 2026, Ball sold 1,533 ADS at a weighted-average price of $405.5528, with reported sale prices ranging from $405.25 to $406.15. He also sold 26 ADS at $406.34. No Rule 10b5-1 plan is reported.

How many ONC ADS did Titus B. Ball acquire?

On November 6, 2026, Ball acquired 880 ADS at $207.55 per share and 679 ADS at $159.03 per share. Each ADS represents 13 ordinary shares.

What were the vesting terms for Titus B. Ball’s options?

The options representing 11,440 ordinary shares vest 25% on August 31, 2024, with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. For the options representing 8,827 ordinary shares, 25% vests on the first anniversary of June 5, 2024, followed by 36 equal monthly installments, subject to continued service; unvested securities are subject to accelerated vesting upon certain termination events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ball Titus B.

(Last)

(First)

(Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL

4051

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares								97,929	D
American Depositary Shares⁽¹⁾	11/06/2026		M		880	A	$207.55	880	D
American Depositary Shares⁽¹⁾	11/06/2026		M		679	A	$159.03	1,559	D
American Depositary Shares⁽¹⁾	11/06/2026		S		1,533	D	$405.5528⁽²⁾	26	D
American Depositary Shares⁽¹⁾	11/06/2026		S		26	D	$406.34	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$15.97	11/06/2026⁽³⁾		M			11,440	⁽⁴⁾	08/30/2033	Ordinary Shares	11,440	$0	3,237	D
Share Option (Right to Buy)	$12.23	11/06/2026⁽³⁾		M			8,827	⁽⁵⁾	06/04/2034	Ordinary Shares	8,827	$0	6,513	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $405.25 to $406.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

4. These securities vest over a four-year period as follows: 25% on August 31, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service.

5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

Exhibit List - Exhibit 24.1 - Power of Attorney

	/s/ Frank Collazo, as Attorney-in-Fact	11/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR